Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 8;39(11):1461-1463.
doi: 10.1016/j.ccell.2021.10.005. Epub 2021 Nov 8.

T cell engagers in solid tumors kick the door down

Maria de Miguel  1 , Emiliano Calvo  2
Affiliations
Free article
Comment

T cell engagers in solid tumors kick the door down

Maria de Miguel et al. Cancer Cell. .
Free article

Abstract

Tebentafusp, a T cell-redirecting, bispecific-antibody-targeting, HLA∗02:01-restricted gp100 peptide and CD3, induces T cells to kill glycoprotein 100 (gp100)-expressing tumor cells. Tebentafusp is the first T cell engager to show a statistically significant overall survival improvement for the treatment of patients with solid tumors, and this has been reported in the New England Journal of Medicine.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.d.M. reports research funding from MSD, Pharmamar, Roche, Novartis, Abbvie, Array, Eisai, and Sanofi; and Speaker’s Bureau membership for MSD, Janssen, and Roche. E.C. reports advisory honoraria from Adcendo, Alkermes, Amunix, Anaveon, Amcure, AstraZeneca, BMS, Janssen, MonTa, MSD, Nanobiotix, Nouscom, Novartis, OncoDNA, PharmaMar, Roche/Genentech, Saofi, Servier, SyneosHealth, TargImmune, and T-knife; research grants from Achilles and BeiGene; steering committee memberships and IDMC participation for BeiGene (IDMC steering committee), EORTC (IDMC chair, non-financial interest), MedSIR (steering committee), and Novartis (steering committee); scientific board membership for Adcendo, Chugai Pharmaceuticals, and PsiOxus Therapeutics; and employment with HM Hospitals Group and START Program of Early Phase Clinical Drug Development in Oncology. E.C. is also a medical oncologist, clinical investigator, and director of clinical research; an owner of the START corporation, Oncoart Associated, and International Cancer Consultants; and founder and president of the non-for-profit foundation INTHEOS (Investigational Therapeutics in Oncological Sciences).

Comment on

  • Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators. Nathan P, et al. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. N Engl J Med. 2021. PMID: 34551229 Clinical Trial.

LinkOut - more resources